Sinopharm Group Co. Ltd.
1099
Clasificación en acciones
#2926
Sinopharm Group Co. Ltd. is a prominent player in the People's Republic of... Sinopharm Group Co. Ltd. is a prominent player in the People's Republic of China's healthcare market, specializing in the wholesale and retail of pharmaceuticals, medical devices, and related health products. The company's business activities are organized across four main divisions. Its Pharmaceutical Distribution segment supplies pharmaceutical goods to a wide range of clients, including hospitals, fellow distributors, retail pharmacies, and clinics. This division additionally offers extensive distribution, logistics, and value-added support to both domestic and international manufacturers and suppliers in the pharmaceutical and healthcare sectors. The Medical Devices segment is solely focused on the distribution of various medical equipment. Through its Retail Pharmacy division, Sinopharm manages and franchises a vast chain of drug stores, with an impressive 10,259 locations as of December 31, 2021. The "Other Business" segment is involved in the manufacturing and sale of pharmaceutical products, chemical reagents, and laboratory supplies. Beyond these core areas, the company also engages in property rental and management. It further distributes specialized items such as medical instruments, traditional Chinese herbal medicines, antibiotics, and biological products. Sinopharm provides a comprehensive array of services, including IT development, medicine and health consultations, investment services, import/export facilitation for goods and technology, various business and market information consulting, and the organization of conventions and exhibitions. Moreover, it oversees medical project investments, offers related consulting, and provides technological training. Notably, Sinopharm Group has established a strategic alliance with I-Mab to enhance its commercial capabilities and accelerate its market entry strategies. Founded in Shanghai, China, in 2003, Sinopharm Group Co. Ltd. operates as a subsidiary of Sinopharm Industrial Investment Co., Ltd.
Precio por acción
$2.02
Capitalización bursátil
$6.31B
Cambio (1 día)
2.80%
Cambio (1 año)
-16.09%
País
CN
Comercio Sinopharm Group Co. Ltd. (1099)
Categoría
Healthcare
Ratio P/E de Sinopharm Group Co. Ltd. (1099)
Ratio P/E al October 2026 TTM: 5.95
Según los últimos informes financieros y el precio de las acciones de Sinopharm Group Co. Ltd., el P/E actual (TTM) de la empresa es 5.95. Al final de 2023, la empresa tenía un P/E de 6.31.
Historial del ratio P/E de Sinopharm Group Co. Ltd. desde 2006 hasta 2026
Relación P/E al final de cada año
| Año | Ratio P/E | Cambiar |
|---|---|---|
| 2026 (TTM) | 5.95 | -32.88% |
| 2024 | 8.86 | 40.36% |
| 2023 | 6.31 | -1.62% |
| 2022 | 6.41 | 15.78% |
| 2021 | 5.54 | -19.36% |
| 2020 | 6.87 | -3.35% |
| 2019 | 7.11 | -22.00% |
| 2018 | 9.11 | -15.07% |
| 2017 | 10.73 | -36.83% |
| 2016 | 16.98 | -11.33% |
| 2015 | 19.15 | -3.06% |
| 2014 | 19.76 | 1.48% |
| 2013 | 19.47 | -17.93% |
| 2012 | 23.72 | 3.89% |
| 2011 | 22.83 | -46.94% |
| 2010 | 43.03 | -17.01% |
| 2009 | 51.85 | 59.01% |
| 2008 | 32.61 | -38.42% |
| 2007 | 52.95 | -68.18% |
| 2006 | 166.42 | 0.00% |
Relación P/E para empresas similares o competidores
| Empresa | P/E Ratio | Diferencia del P/E Ratio | País |
|---|---|---|---|
| 26.02 | 337.53% |
US
|
|
| - | - |
US
|
|
| 34.08 | 472.99% |
US
|
|
| - | - |
US
|
|
| 45.62 | 667.03% |
AU
|
¿Cómo leer un P/E ratio?
El ratio Precio/Beneficio (P/E Ratio) mide la relación entre el precio de las acciones de una empresa y sus beneficios por acción.
Un P/E bajo pero positivo indica una empresa con altos beneficios en relación a su valoración actual y que podría estar infravalorada. Una empresa con un P/E negativo alto (cerca de 0) indica fuertes pérdidas en comparación con su valoración.
Las empresas con un P/E superior a 30 o negativo suelen considerarse "acciones de crecimiento", lo que significa que los inversores esperan que crezca o se vuelva rentable en el futuro.
Las empresas con un P/E positivo inferior a 10 suelen considerarse "acciones de valor", lo que significa que ya son muy rentables y no se espera un fuerte crecimiento.